Goldman Sachs’ top economists and strategists discuss revised forecasts for the US economy and corporate earnings and the prospect of federal stimulus programs in the face of the COVID-19 outbreak. https://www.goldmansachs.com/insights/podcasts/episodes/03-23-2020-jan-hatzius.html
Coronavirus Update from Goldman Sachs’ Sharmin Mossavar-Rahmani as he chats with industry leading CEO and health experts on a search for a therapy or vaccine for Coronavirus.
Dr. Thomas Schinecker, CEO of Roche Diagnostics
Steve Rusckowski, CEO of Quest Diagnostics
Dr. Leonard Schleifer, MD, CEO of Regeneron
Stéphane Bancel, CEO of Moderna
Pablo Tebas, MD, University of Pennsylvania and National Institute of Health Supported Investigator
Peter Slavin, MD, President, Massachusetts General Hospital
Dr. Barry Bloom, Harvard T.H. Chan School of Public Health
Editor’s note: This article has been updated since its original publication to include recently released data and commentary.
“As economies reopen and more workers return to their jobs, mobility trends and production levels should further improve.” ~ Chetan Ahya, Chief Global Economist, Morgan Stanley Research
Can the global economy, which began the year on the path to recovery, get past the coronavirus outbreak and back on the road to growth? Update on the Coronavirus Recession, the Monetary and Fiscal Response and a Late-Cycle Recovery.
We’ve been here before…
As you know, market downturns and bouts of volatility aren’t rare events—even those that grow out of health crises such as the SARS (severe acute respiratory syndrome) outbreak in 2003 and the Zika virus outbreak in 2016.
View Vanguard’s guide on navigating short-term volatility as compared to previous health crises. View Guide
|March Chart Pack|
|We “chart-ify” the current market each month to help you position for what lies ahead. |
The March Chart Pack tells a tale of:
Covid-19: The impact of this selloff doesn’t discriminate
Rates: After an emergency cut, what’s the probability of another?
Gold: The current rally may still have room to riseAnd so much more…
For Investment Professional Use Only.
Important Risk Information
Investing involves risk, including the risk of loss of principal.
The information provided does not constitute investment advice and it should not be relied on as such. It should not be considered a solicitation to buy or an offer to sell a security. It does not take into account any investor’s particular investment objectives, strategies, tax status or investment horizon. You should consult your tax and financial advisor.
State Street Global Advisors and its affiliates have not taken into consideration the circumstances of any particular investor in producing this material and are not making an investment recommendation or acting in fiduciary capacity in connection with the provision of the information contained herein.
Intellectual Property Information: Standard & Poor’s®, S&P® and SPDR®, are registered trademarks of Standard & Poor’s Financial Services LLC, a division of S&P Global (“S&P”); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (Dow Jones); and these trademarks have been licensed for use by S&P Dow Jones Indices LLC (SPDJI) and sublicensed for certain purposes by State Street Corporation. State Street Corporation’s financial products are not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, their respective affiliates and third-party licensors and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability in relation thereto, including for any errors, omissions, or interruptions of any index.
State Street Global Advisors Funds Distributors, LLC, member FINRA, SIPC.
© 2020 State Street Corporation. All Rights Reserved.
Exp. Date: 4/30/2020